Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

pharma 1 > Anticancer drugs > Flashcards

Anticancer drugs Flashcards

1
Q

Alemtuzumab

TARGET and ADVERSEEFFECT S

A

CD52
increase risk of infections and
autoimmunity (eg, Immune thrombocytopenia(ITP)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

CD52
increase risk of infections and
autoimmunity (eg, Immune thrombocytopenia(ITP)

A

Alemtuzumab

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Bevacizumab

TARGET and ADVERSEEFFECT S

A

VEGF (inhibits blood vessel
formation)

Hemorrhage, blood clots,
impaired wound healing

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

VEGF (inhibits blood vessel
formation)

Hemorrhage, blood clots,
impaired wound healing

A

Bevacizumab

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Cetuximab,panitumumab

A

EGFR
Rash, elevated LFTs, diarrhea

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

EGFR
Rash, elevated LFTs, diarrhea

monoclonal antibodie

A

Cetuximab,panitumumab

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

CD20
Non-Hodgkin lymphoma,
CLL, rheumatoid arthritis,
ITP, TTP, AIHA, multiple
sclerosis

A

Rituximab

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Rituximab

target and clinical use

A

CD20

Non-Hodgkin lymphoma,
CLL, rheumatoid arthritis,
ITP, TTP, AIHA, multiple
sclerosis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Trastuzumab

target and adverseeffect

A

HER2

(“trust HER”) Dilated cardiomyopathy (often reversible)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

HER2
​
(“trust HER”) Dilated cardiomyopathy (often reversible)

A

Trastuzumab

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Pembrolizumab,
nivolumab,
cemiplimab

A

PD-1
increase risk of autoimmunity (eg, dermatitis, enterocolitis,
hepatitis, pneumonitis, endocrinopathies)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

PD-1
increase risk of autoimmunity (eg, dermatitis, enterocolitis,
hepatitis, pneumonitis, endocrinopathies)

A

Pembrolizumab,
nivolumab,
cemiplimab

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Atezolizumab,
durvalumab,
avelumab

A

PD-L1
increase risk of autoimmunity (eg,
dermatitis, enterocolitis,
hepatitis, pneumonitis,
endocrinopathies

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Ipilimumab

A

CTLA-4
increase risk of autoimmunity (eg, dermatitis, enterocolitis,
hepatitis, pneumonitis,endocrinopathies)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

CTLA-4
increase risk of autoimmunity (eg, dermatitis, enterocolitis,
hepatitis, pneumonitis,endocrinopathies)

A

Ipilimumab

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

ALK
Edema, rash, diarrhea

A

Alectinib,crizotinib

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Alectinib,crizotinib

A

ALK
Edema, rash, diarrhea

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

EGFR
Rash, diarrhea

A

Erlotinib, gefitinib,
afatinib

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Erlotinib, gefitinib,afatinib

A

EGFR
Rash, diarrhea

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

BCR-ABL
Myelosuppression, increase LFTs,
edema, myalgias

A

Imatinib, dasatinib,
nilotinib

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Imatinib, dasatinib,
nilotinib

A

BCR-ABL
Myelosuppression, increase LFTs,
edema, myalgias

22
Q

JAK1/2 Bruises, increase LFTs

A

Ruxolitinib

23
Q

Ruxolitinib

A

JAK1/2 Bruises, increase LFTs

24
Q

Proteasome (induce
arrest at G2-M phase via
accumulation of abnormal
proteins leading to apoptosis).

Peripheral neuropathy, herpes
zoster reactivation (decrease T-cell
activation leading to deacrese cell-mediated
immunity)

A

Bortezomib, ixazomib,
carfilzomib

25
Q

Bortezomib, ixazomib,
carfilzomib

A

Proteasome (induce
arrest at G2-M phase via
accumulation of abnormal
proteins leading to apoptosis).

Peripheral neuropathy, herpes
zoster reactivation (decrease T-cell
activation leading to deacrese cell-mediated
immunity)

26
Q

BRAF
Rash, fatigue, nausea, diarrhea

A

Vemurafenib,
encorafenib,
dabrafenib

27
Q

Vemurafenib,
encorafenib,
dabrafenib

A

BRAF
Rash, fatigue, nausea, diarrhea

28
Q

Cyclin-dependent kinase 4/6
(induces arrest at G1-S phase
leading to apoptosis)

Myelosuppression, pneumonitis

A

Palbociclib

29
Q

Poly(ADP-ribose) polymerase
(decrease DNA repair)

Myelosuppression, edema, diarrhea

A

Olaparib

30
Q

Olaparib

A

Poly(ADP-ribose) polymerase
(decrease DNA repair)
​
Myelosuppression, edema, diarrhea

31
Q

Free radical scavenger
Nephrotoxicity from platinum compounds

MECHAN ISM , CL INICAL USE

A

Amifostine

32
Q

Iron chelator
Cardiotoxicity from anthracyclines

MECHAN ISM , CL INICAL USE

A

Dexrazoxane

33
Q

Tetrahydrofolate precursor

Myelosuppression from methotrexate (leucovorin “rescue”); also enhances the effects of 5-FU

MECHAN ISM , CL INICAL USE

A

Leucovorin (folinic
acid)

34
Q

-Sulfhydryl compound that binds acrolein (toxic
metabolite of cyclophosphamide/ifosfamide)

-Hemorrhagic cystitis from cyclophosphamide/
ifosfamide

MECHAN ISM , CL INICAL USE

A

Mesna

35
Q
  • Recombinant uricase that catalyzes metabolism
    of uric acid to allantoin
    -Tumor lysis syndrome

MECHAN ISM , CL INICAL USE

A

Rasburicase

36
Q

Amifostine

MECHAN ISM , CL INICAL USE

A

Free radical scavenger
Nephrotoxicity from platinum compounds

37
Q

Dexrazoxane

MECHAN ISM , CL INICAL USE

A

Iron chelator
Cardiotoxicity from anthracyclines

38
Q

Leucovorin (folinic acid)

MECHAN ISM , CL INICAL USE

A

Tetrahydrofolate precursor
Myelosuppression from methotrexate (leucovorin “rescue”); also enhances the effects of 5-FU

39
Q

Mesna

MECHAN ISM , CL INICAL USE

A

-Sulfhydryl compound that binds acrolein (toxic
metabolite of cyclophosphamide/ifosfamide)

-Hemorrhagic cystitis from cyclophosphamide/
ifosfamide

40
Q

Rasburicase

MECHAN ISM , CL INICAL USE

A

-Recombinant uricase that catalyzes metabolism
of uric acid to allantoin

-Tumor lysis syndrome

41
Q

5-HT3 receptor antagonists
Acute nausea and vomiting

MECHAN ISM , CL INICAL USE

A

Ondansetron, granisetron

42
Q

D2 receptor antagonists
Acute nausea and vomiting

A

Prochlorperazine, metoclopramide

43
Q

NK1 receptor antagonists
Delayed nausea and vomiting (>24 hr after chemotherapy)

A

Aprepitant,fosaprepitant

44
Q

Recombinant G(M)-CSF Neutropenia

A

Filgrastim,
sargramostim

45
Q

Recombinant erythropoietin Anemia

A

Epoetin alfa

46
Q

Ondansetron, granisetron

MECHAN ISM , CL INICAL USE

A

5-HT3 receptor antagonists
Acute nausea and vomiting

47
Q

Prochlorperazine, metoclopramide

MECHAN ISM , CL INICAL USE

A

D2 receptor antagonists
Acute nausea and vomiting

48
Q

Aprepitant,
fosaprepitant

A

NK1receptor antagonists
Delayed nausea and vomiting

49
Q

Filgrastim,
sargramostim

A

Recombinant G(M)-CSF
Neutropenia

50
Q

Epoetin alfa

A

Recombinant erythropoietin
Anemia

pharma 1 (13 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions